Last updated on March 2019

A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)

Brief description of study

This Phase 3, multicenter, randomized, double-blind, placebo controlled study is designed to evaluate the efficacy and safety of atezolizumab (MPDL3280A, an anti-programmed death-ligand 1 [PD-L1] antibody) administered in combination with paclitaxel compared with placebo in combination with paclitaxel in participants with previously untreated, inoperable locally advanced or metastatic, centrally confirmed TNBC. Participants will be randomized in a 2:1 ratio to receive atezolizumab or placebo plus paclitaxel until disease progression or unacceptable toxicity or end of study, whichever occurs first (maximum up to approximately 45 months).

Clinical Study Identifier: NCT03125902

Contact Investigators or Research Sites near you

Start Over

Stanford Cancer Center

Stanford, CA United States
  Connect »

Northwestern University

Chicago, IL United States
  Connect »

The Valley Hospital

Paramus, NJ United States
  Connect »

Magee-Woman's Hospital

Pittsburgh, PA United States
  Connect »

CHD Les Oudairies

La Roche Sur Yon, France
  Connect »

Petrov Research Inst. of Oncology

St Petersburg, Russian Federation
  Connect »

Christie Hospital

Manchester, United Kingdom
  Connect »

Mount Vernon Cancer Centre

Northwood, United Kingdom
  Connect »

K hospital

Hanoi, Vietnam
  Connect »

Western General Hospital

Edinburgh, United Kingdom
  Connect »

Florida Cancer Specialist, North Region

Saint Petersburg, FL United States
  Connect »

HCA Midwest Health

Kansas City, MO United States
  Connect »

Mammacentrum sv. Ag ty

Banská Bystrica, Slovakia
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.